e CMHC and professor of medicine at the University of Colorado Anschutz Medical Campus remarked, “The FDA decision to approve lomitapide provides a new option for patients with HoFH, who so often develop extensive atherosclerotic cardiovascular disease as children, and remain inadequately treated.” Christie Ballantyne, MD, co-chair of the CMHC, chief, Section of Cardiovascular Research and Cardiology at Baylor College of Medicine and director of the Center for Cardiovascular Disease Prevention at Methodist DeBakey Heart and Vascular Center echoed a similar sentiment: “I am excited that we will have a new treatment option available for patients with HoFH.”
Sergio Fazio, MD, PhD, the Cornelius Vanderbilt Professor of Medicine and Pathology at Vanderbilt University School of Medicine in Nashville, Tenn., and chief of the Section of Cardiovascular Disease Prevention, cited the significance of the lomitapide approval: “This novel therapy is at the other end of the spectrum of cholesterol-lowering therapies – not a drug for everyone, like the statins, but an extreme intervention for extreme situations. Its mechanism of action is based on the inhibition of MTP, an intracellular protein that moves the lipid droplet to the forming lipoprotein in the liver and intestine. By targeting lipoprotein assembly, lomitapide has the power to reduce cholesterol irrespective of the type of mutation causing FH, since its effect is not based on up-regulation of the LDL receptor.”
Convening Oct. 2–5, 2013, in Boston, the CMHC is co-chaired by George L. Bakris, MD; Christie M. Ballantyne, MD; Robert H. Eckel, MD; and Jay S. Skyler, MD, MACP. The CMHC provides the most advanced-level cardiometabolic education encompassing a multitude of risk factors, including cardiovascular disease, obesity, type 2 diabetes, dyslipidemia, atherosclerosis, hypertension, thrombosis, acute coronary syndrome, chronic kidney disease and related comorbidities.
For more information, contac
'/>"/>
Source: PRWeb Copyright©2012 Vocus, Inc. All rights reserved | |
Page: 1 2 3 Related biology technology :1.
Midwest Healthcare Startups Raise $996 Million in 20122.
HealthEconomics.Com Appoints New Director of Information Technology and Operations3.
Join Cato BioVentures and Cancer Advances at Biotech Showcase 2013 & J.P. Morgan 31st Annual Healthcare Conference4.
BulletinHealthcare a TOP 10 “Most Innovative Company” of 2012 According to Pharma Marketing Publication PM3605.
First Maryland Hospital Offering 3D Mammograms? VA Maryland Health Care System6.
Opedix® Kinetic Health Gear Unveils New KNEE-Tec™ Knee Support Tights Shown to Reduce Quadriceps Muscle Fatigue and Knee Pain7.
The Medzilla Employment Report for December, 2012: Unemployment Drops to Lowest Rate in 4 Years; Experts Predict Unprecedented Growth in Healthcare IT8.
Life Solutions Advocates Announces New Partnerships in Health Promotion and Disease Prevention Initiative9.
Trending HealthEconomics.Com Pharma Pricing, Reimbursement, and Health Policy Stories Feature Rising Trend in Pharma Price Cuts to Secure Reimbursement10.
Insmed to Present at 31st Annual J.P. Morgan Healthcare Conference11.
Analysis of Venture Capital Investment Trends in the North American and European Healthcare Industry